# A Study of BBI608 in Adult Patients With Advanced, Refractory Hematologic Malignancies

> **NCT02352558** · PHASE1 · COMPLETED · sponsor: **Sumitomo Pharma America, Inc.** · enrollment: 15 (actual)

## Conditions studied

- Hematologic Malignancy

## Interventions

- **DRUG:** BBI608
- **DRUG:** Dexamethasone
- **DRUG:** Bortezomib
- **DRUG:** Imatinib
- **DRUG:** Ibrutinib

## Key facts

- **NCT ID:** NCT02352558
- **Lead sponsor:** Sumitomo Pharma America, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-05
- **Primary completion:** 2018-12-14
- **Final completion:** 2019-05-16
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2023-11-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02352558

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02352558, "A Study of BBI608 in Adult Patients With Advanced, Refractory Hematologic Malignancies". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02352558. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*